 |
Medscape Conference Coverage, based on selected sessions at the: 30th Annual San Antonio Breast Cancer Symposium (SABCS) December 13 - 16, 2007, San Antonio, Texas This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium.
Topic Overviews- CME Early Stage Breast Cancer
Physicians - maximum of 0.75 AMA PRA Category 1 credit(s)™ - Update on Radiation Therapy for Breast Cancer
Pauline T. Truong, MD, FRCPC - New Tools for Predicting Benefit From Adjuvant Breast Cancer Therapy
Joseph A. Sparano, MD
- CME Adjuvant Treatment of Breast Cancer
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ - Adjuvant Therapy for HER2-Normal Early-Stage Breast Cancer
Heather McArthur, MD; Clifford Hudis, MD - Endocrine Therapy: Highlights From SABCS 2007
Harold J. Burstein, MD, PhD - What's New in HER2-Targeted Therapy for Breast Cancer?
Susanne Briest, MD; Antonio C. Wolff, MD
- CME Improving Outcomes in Advanced and Metastatic Breast Cancer
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ - Current Front-line Treatment for Metastatic Breast Cancer
Kathy D. Miller, MD - Emerging Options for Treatment-Refractory Advanced Breast Cancer
Lawrence N. Shulman, MD; Erica L. Mayer, MD, MPH - Optimizing Treatment of "Triple-Negative" Breast Cancer
Eric P. Winer, MD; Erica L. Mayer, MD, MPH
Conference SpotlightsExpert InterviewsConference News- Alphavbeta6 Potential New Target for Aggressive Breast CancersThe epithelial-specific integrin alphavbeta6 is showing promise as a possible therapeutic target for poor-prognosis breast cancers.
Medscape Medical News, January 11, 2008 - CME Healthy Diet May Not Reduce Breast Cancer Recurrence or MortalityResults of the Women's Healthy Eating and Living Study are in, and the results appear disappointing for breast cancer patients.
Medscape Medical News, December 21, 2007 - Tamoxifen Benefit in Breast Cancer Appears to Extend Beyond 5 YearsThe largest trial to date testing adjuvant therapy in breast cancer has found that, contrary to National Cancer Institute recommendations, tamoxifen can likely be continued beyond 5 years.
Medscape Medical News, December 19, 2007 - Circulating Tumor Cells an Early Indicator of Response to Breast Cancer TreatmentA drop in circulating tumor cells (CTCs) indicates that chemotherapy is working in patients with metastatic breast cancer. This can be established within a few weeks after the first cycle of treatment, a Georgetown University team reported at the annual San Antonio Breast Cancer Symposium.
Reuters Health, December 18, 2007 - Florida Program Gets Women With Suspicious Mammogram to Early TreatmentMost women with positive findings on screening mammography are diagnosed and started on treatment within 60 days of screening in a program designed and implemented by researchers at the Mayo Clinic in Jacksonville, Florida.
Reuters Health, December 18, 2007 - CME Long-Term Data Back Anastrozole Over Tamoxifen in Breast CancerAnastrozole offers long-term efficacy over tamoxifen, and the benefits of treatment are maintained long after therapy is completed, a trial shows.
Medscape Medical News, December 17, 2007 - Outcome of HER-2-Positive Breast Cancer Tied to Hormone Receptor StatusHER-2-positive, hormone receptor-negative breast cancer patients have a high risk of failure after chemotherapy, and the most common site of cancer recurrence after treatment failure is the brain, Mayo Clinic researchers reported at the San Antonio Breast Cancer Symposium.
Reuters Health, December 17, 2007 - Small Tumors Are Aggressive in HER2-Positive Breast CancerBreast cancer tumors only a centimeter in diameter or less, without node involvement, can still be aggressive and carry a poor prognosis in a subset of patients, a team comprised of researchers from all three Mayo Clinics reported at the San Antonio Breast Cancer Symposium.
Reuters Health, December 17, 2007 - Denosumab Useful in Treating Aromatase-Inhibitor-Induced Bone LossWith a different mechanism of action than current options, denosumab is showing promise for breast cancer patients with aromatase-inhibitor-induced bone loss.
Medscape Medical News, December 16, 2007 - Long-Term Results Support Hypofractionated Whole-Breast IrradiationResearchers are encouraging broader use of hypofractionated irradiation in early breast cancer.
Medscape Medical News, December 14, 2007 - High-Dose Chemo With HSCT Outdated for Breast CancerNo overall survival benefit is gained with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) for women with early breast cancer and multiple positive nodes.
Reuters Health, December 14, 2007 - Breast Cancer Survival Longer With Docetaxel Than DoxorubicinThe long-term findings of a large, multicenter study show that breast cancer survival is significantly improved and adverse effects are significantly less severe with docetaxel (Taxotere) than with doxorubicin (Adriamycin).
Reuters Health, December 13, 2007
|
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2007 Medscape. |
|
|
